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Abstract 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by abnormal autoantibody production 
and clearance. This immunological background has been suggested to play a role in the susceptibility of SLE patients to 
infection. Moreover, drugs (most of them immunosuppressive or immunomodulating agents) used in the treatment of 
moderate and severe lupus give rise to a tendency for infections, including opportunistic ones. Infections may mimic the 
exacerbations of SLE, leading to confusion over the diagnosis and appropriate treatment. Despite increased awareness of 
this problem, infections remain a major source of morbidity and mortality in SLE. There are various strategies which can be 
applied to try and reduce the risk of infection in SLE patients. Options include vaccinations, antibiotic/antiviral prophylaxis 
and intravenous immunoglobulins. 
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Abbreviations 
ANA anti-nuclear antibody 
C1q complement factor 1q 
C3 complement factor 3 
CMV cytomegalovirus 
CRP C-reactive protein 
CVID common variable immunodeficiency 
DNA deoxyribonucleic acid 
ESR erythrocyte sedimentation rate 
EULAR European League against Rheumatism 
H1N1 haemagluttinin 1, neuraminidase 1 
HIV human immunodeficiency virus 
HPV human papilloma virus 
iC3b inactive C3b 
IVIg intravenous immunoglobulin 
MBL mannose binding lectin 
MMR mumps, measles, rubella 
PCR polymerase chain reaction 
PJP Pneumocystis jiroveci pneumonia 
SLE systemic lupus erythematosus 
Sm Smith 
SLEDAI Systemic Lupus Erythematosus Disease Activity Index 
 
Introduction 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by abnormal autoantibody 
production and clearance. This immunological background has been suggested to play a role in the susceptibility 
of SLE patients to infections [1]. Moreover, drugs (most of them immunosuppressive or immunomodulating 
agents) used in the treatment of moderate and severe lupus give rise to a tendency for infections, including 
opportunistic ones. 
 
Infections may mimic the exacerbations of SLE, leading to confusion over the diagnosis and appropriate 
treatment. Despite increased awareness of this problem, infections remain a major source of morbidity and 
mortality in SLE. Infectious diseases are still the most frequent causes of death in SLE in the first year after onset 
[2]. The increase in SLE deaths associated with infection, especially pneumonia and septicaemia, is worrisome, 
especially in some areas of the globe [3]. Indeed, survival rates for SLE patients in developing countries are 
comparatively lower than those reported in industrialised countries, with early death from infection and active 
disease [4]. 
 
In this review, we aim to review infections in SLE and appropriate prevention strategies. 
 
Characteristics of infection in SLE 
Infections are known to be a major cause of morbidity and mortality in SLE [1]. Several studies evaluated the 
characteristics of major infections in SLE patients requiring hospitalisation [5], *[6] and [7]. According to these 
studies, infections that SLE patients developed were attributed to the same pathogens as in the general 
population and included community-acquired pneumonia, urinary tract infection and vaginal infection, and 
some patients may develop tuberculosis. However, despite the pathogens often being the same as in the 
general population, the clinical manifestations of the infections can be atypical, due to an abnormal 
immunological response or due to ongoing treatment. Careful inspection and monitoring and timely collection 
of the specimens for bacterial culture are warranted to avoid misdiagnosis. 
Some patients also develop viral, fungal and protozoan infections. Rarely, multiple organisms can be found [8]. 
Usually, in an outpatient setting, infections are non-life-threatening ones. Zonana-Nacach et al. reported that in 
this scenario, infections are associated with disease activity only, independently of socio-demographic and 
therapeutic factors [5]. However, it is noteworthy that infection in SLE can require hospitalisation, especially 
when concomitant with a flare (mainly involving the kidney or central nervous system) or when therapy with 
steroids or cyclophosphamide is ongoing [1]. 
 
Predictors of major infections in SLE 
Several studies have analysed the prevalence and associated clinical and laboratory features of infection in SLE 
*[8], [9], [10] and [11]. Common themes are medications, including use of steroids and/or cyclophosphamide or 
high-disease activity as measured by the SLE Disease Activity Index [12]. 
Recently, Ruiz-Irastorza and co-workers [13] in a nested case–control study design used within the prospective 
Lupus-Cruces cohort analysing 249 patients found that the risk of major infections in patients with SLE is mostly 
influenced by treatment. Prednisone treatment, even at moderate doses, increases the risk, whilst antimalarials 
have a protective effect [13]. In detail, it was shown that the prednisone dose at the time of the event had a 
facilitating effect on infections, in agreement with previous studies [9], [10] and [11]. Moreover, it is worthy of 
note that the median dose of patients with major infections was only 7.5 mg day−1, with an 11-times higher risk 
of suffering a serious infection for each increase of 10-mg day−1 prednisone. 
 
SLE, infections and mortality 
When the frequency, characteristics of the main causes and prognostic significance for morbidity and mortality 
in 1000 patients with SLE during a 5-year period were analysed, the most frequent causes of death were active 
SLE, infections and thromboses [14]. In the long-term follow-up of the same study, infection was the present in 
36% of the 1000 patients and most frequent causes of death were confirmed to be similarly divided among 
active SLE (26.5%), thromboses (26.5%) and infections (25%). A survival probability of 92% at 10 years was found 
[15]. 
 
In a retrospective study performed to describe the characteristics associated with a poor outcome in SLE 
patients admitted to hospital during a 1-year period, infection was found to be the second cause of 
hospitalisation after clinical flare of SLE [16]. 
 Infections according to nature of microbe 
Bacterial infections 
A wide variety of infectious pathogens have been recognised in SLE. The most frequent types of infections are 
respiratory, urinary tract and soft-tissue infections [12]. Most infections are caused by common pathogens and 
include Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli and Pseudomonas aeruginosa. 
Indeed, common pathogens that often behave more aggressively than in the healthy population. *[12] and *[17] 
An increased incidence of Salmonella infection and pneumococcal sepsis is also observed [18]. 
 
S. pneumoniae 
S. pneumoniae is a Gram-positive bacterium, which is a common cause of community-acquired pneumonia, 
meningitis and septicaemia. Several studies indicate that patients with SLE have an increased frequency and 
severity of S. pneumoniae infections, accounting for 6–18% of all bacterial infections in these patients *[17] and 
[20]. It has been suggested that some defective mechanisms in SLE patients can underpin this increased 
susceptibility to S. pneumoniae infections. Recently, Goldblatt et al. [20] reported that opsonisation of S. 
pneumoniae with complement factor 3b/inactive C3b (C3b/iC3b) was significantly reduced in serum from 
patients with SLE compared with patients with non-SLE rheumatic disease and healthy controls, suggesting that 
a failure to appropriately activate the immune system via complement may contribute to the increased 
susceptibility of SLE subjects to infections and may correlate with a risk of pneumonia in a subgroup of SLE 
patients. 
 
Salmonella 
Infection with Salmonella species is recognised to be more common in SLE patients than the normal population 
and may be due to splenic dysfunction or to a defect in opsonisation as previously described [19] and [20]. The 
risk factors of mortality for Salmonella infection have been recently analysed in a cohort of SLE patients 
hospitalised in a medical centre in Taiwan [21]. Patients with Salmonella infection associated with lupus flare or 
re-infection with Salmonella species have been found to be the strongest factor associated with a higher risk of 
mortality [21]. In another study, retrospectively reviewing 50 SLE patients diagnosed with bacteriologically 
proven non-typhoidal salmonellosis over a 20-year period, it was found that most episodes were bacteraemic 
without a localising focus, and some patients were afebrile. Mortality in general occurred from concomitant 
septic shock and major organ failure from active lupus (mainly renal) [22]. It is noteworthy that osteomyelitis of 
the long bones due to salmonella can occur in SLE patients [23]. Active SLE or co-existent underlying systemic 
disease, chronic renal failure, and immunosuppressive agents were shown as main predisposing factors [23]. 
Recently, Navarra et al. [24] described the spectrum of Salmonella infections among Filipino patients with SLE, 
with typhoid fever and septic arthritis as the most common presentation. Atypical involvement included soft-
tissue abscess and meningitis, with the worst prognosis noted in those with sepsis syndrome. 
 
Klebsiella 
Some studies showed that Klebsiella was one of the leading causes of Gram-negative bacteraemia in the general 
population [25]. SLE patients infected with Klebsiella were found to have lower probabilities of 14-day survival 
[26] in a study analysing the short-term survival of patients with SLE after bacteraemia episodes. 
 
It is noteworthy that sera from patients with Klebsiella pneumoniae were found to contain high titres of the 
common anti-DNA idiotype [27]. However, the presence of autoantibodies in the serum of patients with 
Klebsiella infections may be the result of non-specific stimulation due to bacterial polyclonal activation. 
However, there might also be a specific stimulus triggered by idiotypic cross-reaction between autoantibodies 
and anti-Klebsiella antibodies [28]. 
 
Mycobacterium tuberculosis 
The reported prevalence of M. tuberculosis infection in SLE patients ranges widely from 5% to 30% [29] and 
[30]. The higher prevalence of tuberculous infections in SLE is attributed to multiple immune abnormalities 
observed in these patients and to the immunosuppressant therapy [31]. The clinical presentation of M. 
tuberculosis infection seems to be different in SLE patients when compared with the general population; in fact, 
more frequent extrapulmonary involvement as well as more extensive pulmonary involvement and a high 
relapse rate even if treated with prophylactic isoniazid have been reported [30] and [32]. Mycobacterial 
infection and SLE may have a similar presentation and may mimic each other. In an individual patient, the 
differential diagnosis is crucial. In a retrospective analysis involving more than 3000 SLE patients, Hou et al. [33] 
documented 19 lupus patients with 21 episodes, 10 of which were pulmonary while the other 11 episodes were 
extrapulmonary (joint, cutaneous or visceral-organ involvement). Fever and cough were found to be the most 
common manifestations of tuberculosis. However, Sayarlioglu et al. [34], comparing lupus patients without and 
with tuberculosis, found that arthritis and renal disease were significantly higher in the latter group, underling 
the importance of an accurate diagnostic approach. 
 
Opportunistic infections 
Increasing evidence indicates that opportunistic infections contribute to the infectious mortality in SLE, as stated 
before. The burden of opportunistic infections in SLE is complex; often, they are under-reported due to 
difficulties in diagnosis, as they can mimic or be superimposed upon active lupus. Listeriosis, nocardiosis, 
candidiasis, cryptococcal meningitis, Pneumocystis jiroveci pneumonia (PJP) and invasive aspergillosis are 
described in patients with SLE [1]. Sometimes, even more rare infections are reported to occur in SLE, such as 
haemotrophic mycoplasma [35]. 
Cases of SLE with fungaemia or invasive fungal infection are rare but life-threatening conditions in SLE [36]. 
Severe Candida infection is the most frequently identified opportunistic fungal infection in several SLE series, 
associated with steroid and cytotoxic drug therapy [37]. Nocardial infections have been also described in 
steroid-treated SLE patients, and pneumonia and brain abscess are the most frequent clinical presentations [38] 
and [39]. Taken together, all the studies stressed that active lupus disease (SLEDAI > 7) is probably the main risk 
factor for opportunistic infection. It is noteworthy to remember that low prednisolone doses before fungal 
infection or high prednisolone doses following fungal infection are associated with higher mortality [37]. 
 
Viral infections 
The most commonly reported viral infections in patients who have SLE are parvovirus B19 (HPV-B19) (there are 
more than 30 reports of primary B19 infection reported as lupus-like syndrome) [37] and cytomegalovirus 
(CMV) (predominantly presenting in severely immunosuppressed patients). It is not among the purposes of this 
review to analysis the causative role of virus in the pathogenesis of SLE. Herewith, we focus on the clinical 
settings when the two conditions, SLE and viral infection, co-exist. 
Ramos-Casals et al. [40] described the largest series of acute viral infections in SLE patients. Among 25 patients 
diagnosed with new-onset SLE, HPV-B-19, CMV, Epstein–Barr virus and hepatitis A were concomitantly 
detected. In patients already diagnosed with SLE, symptoms related to infection mimicked a lupus flare due to 
disseminated viral infection and a severe, multi-organ process similar to that described in catastrophic 
antiphospholipid syndrome was reported. Mortality was high, with 12 patients dying due to infection. 
 
Parvovirus B19 
The occurrence of HPV-B19 infection has been documented in patients with SLE, in particular in relation to 
disease onset. The main reported clinical manifestations were fever, articular involvement, cutaneous lesions, 
lymphadenopathy, hepato and/or splenomegaly, serositis, renal involvement and cerebral impairment. 
Cytopaenia was also frequently observed. Thus, the differential diagnosis between HPV-B19 infection and SLE 
flare is a real challenge, also because HPV-B19 infection may induce a serological profile mimicking a flare. 
Elevated titres of double-stranded DNA, Sm (Smith), nuclear ribonucleoprotein, Ro-SSA, La-SSB, cardiolipin 
and/or beta2-glycoprotein I antibodies were reported in concomitant to B19 infection [41]. The B19 infection 
has usually a self-limiting course; nevertheless, in immunocompromised SLE patients symptoms may persist 
several months after the viral infection and induce severe clinical settings. 
 
CMV 
Sekigawa et al. [42], reporting SLE patients with spatially related SLE and CMV, emphasised the main features of 
the complex relationship between SLE and viral infection: a) CMV infection and SLE exacerbation may be 
impossible or difficult to distinguish, b) the development of SLE may be triggered by a CMV infection and 3) 
existing SLE may undergo an exacerbation following a CMV infection. Notably, CMV infection can be considered 
as an opportunistic infection, when affecting SLE patients on chronic steroids and/or immunosuppressive 
agents. Among the possible CMV-related manifestations, retinitis has to be kept in mind, especially when 
ongoing therapy includes both azathioprine and low-dose corticosteroid [43]. 
 
HIV 
Interestingly, SLE has a lower incidence in the human immunodeficiency virus (HIV)-infected population when 
compared to the general population [44]. It has also been suggested that SLE may be influenced by HIV 
infection. It has been suggested that the immunosuppression resulting from HIV infection can prevent the 
emergence of SLE, as the immunosuppressive effect of HIV may inhibit the development of autoimmune 
diathesis [45]. To date, several cases of concomitant association between the two diseases have been reported, 
but the diagnosis was simultaneous in very few of those. Very recently, Carugati et al., reporting two cases and 
review of the literature, concluded that SLE could occur despite the loss of immunocompetence caused by HIV 
infection. Moreover, they stated that SLE and HIV infection might influence each other possibly through 
immunologic mechanisms determining awkward manifestations [46]. 
 
Serological markers of infection in SLE 
Conventional biomarkers of lupus flares are hypocomplementaemia, anti-double-stranded-DNA antibodies and 
erythrocyte sedimentation rate. Their value to predict disease flares and efficacy of therapeutics has been 
proven; however, even taken together, they are not specific and lack diagnostic accuracy in differentiating 
between flares and infections [47]. In SLE, unlike in other rheumatic diseases where increase in levels has been 
observed, changes in C-reactive protein (CRP) level have been less frequently observed during disease flares, 
proposing this marker as a valid tool to discriminate infection and lupus activity [48]. Albeit with some 
limitations (such as the presence of arthritis and serositis), to date CRP levels and erythrocyte sedimentation 
rate/C-reactive protein (ESR/CRP) ratio seem to be the best marker to differentiate SLE activity from infection. 
Other biomarkers such as procalcitonin, and autoantibodies against complement fraction C1q, have been 
investigated to distinguish infections from other inflammatory processes but further studies are warranted. 
 
Prevention of infection in SLE 
As illustrated in the first part of this article, predisposition to infection with microbial agents is a major problem 
in SLE. If patients develop either atypical or recurrent infections, then this is a challenge to the clinician. There is 
a range of predisposing factors which may be present in SLE patients (see Table 1). There are various strategies 
which can be applied to try to reduce the risk of infection in SLE patients. Options include vaccinations, 
antibiotic/antiviral prophylaxis and intravenous immunoglobulins (IVIg). 
 
Vaccinations 
Patients with SLE are at an increased risk of infection, especially if they are taking immunosuppressive 
medication. Vaccination can be considered as a possible strategy. The history of vaccination in SLE patients has 
been controversial. This is because in certain cases, vaccination can trigger a flare of the disease. However, a 
number of reviews have recently been undertaken and seem to be in favour of vaccination, that is, the risk 
benefit is for vaccination to reduce infection risk compared with the risk of flare [49]. In their own practice, the 
authors opt for vaccination unless there is a previous history of vaccination-related disease flare. If possible, 
vaccination should be administered before commencing immunosuppressive medication, as once this is started 
then live vaccines are contraindicated, and responses to non-live vaccines may be suboptimal. Non-live 
(inactivated/killed or subunit) vaccines can be used in patients on immunosuppressant therapy [49]. It is also 
best to vaccinate, if possible, when the lupus is quiescent [50]. 
 
The major questions with respect to vaccination in SLE and other autoimmune rheumatic diseases are as 
follows: 
1. Are they safe? 
2. Do they trigger disease flares? 
3. Do they work? 
4. Which vaccines are important? 
 
Are they safe? 
Killed or subunit vaccines are safe to administer to SLE patients on immunosuppression. However, live vaccines 
are contraindicated in patients on immunosuppressive medications according to expert opinion from European 
League against Rheumatism (EULAR). Expert opinion from EULAR also suggests that vaccines should be 
administered while disease activity is quiescent [50]. Abu-Shakra also suggested avoiding vaccines when lupus is 
very active [51]. 
 
Do they trigger disease flares? 
Vaccines may trigger the generation of autoantibodies, which are usually of short term and of little clinical 
significance. Hence, more commonly, induction of autoantibodies but not autoimmune disease may occur. For 
example, induction of cardiolipin antibodies, but not β2-glycoprotein-I antibodies, was seen in SLE patients and 
healthy controls [52]. However, in individual cases vaccines may cause SLE flares. No specific clinical or 
laboratory variables have been shown to be predictive of flare of systemic lupus erythematosus following 
vaccination [51]. 
 
Do they work? 
Vaccinations, if possible, could be administered before commencing immunosuppressive medication as 
vaccination responses may be blunted in patients receiving high-dose corticosteroids or immunosuppressive 
medication. If possible, the authors suggest vaccination before starting immunosuppressive therapy or biologics. 
For example, rituximab, as a B-cell-depleting medication, has a significant effect on vaccine responses. It is best 
to administer vaccines either 4 weeks before or 6 months after rituximab treatment [50]. 
O'Neill and Isenberg (2006) commented that the majority of SLE patients have an appropriate response to 
vaccination, but a significant minority do not [49]. Response to hepatitis-B vaccination may be impaired and 
serological responses should be assessed post vaccination. They speculated that disease activity or 
immunosuppressive drugs were risk factors of poor response, rather than intrinsic abnormalities of immune 
function in SLE. 
 
Response to influenza vaccination was lower in those SLE patients with haematologic criteria, or on 
prednisolone or of European American ancestry. After vaccination, low respondents were more likely to have 
disease flares and to have increased titres of anti-nuclear antibodies (ANAs) [53]. Azathioprine impaired 
response after influenza vaccination, though most patients still developed protective responses [54] and [55]. 
 
Which vaccines are important? 
Pneumococcus 
Respiratory infections are common in patients with SLE. Vaccination against the Pneumococcus bacterium 
should be with Pneumovax 23, the 23-valent polysaccharide vaccine, as the first line, to give the broadest 
coverage. If the patient does not respond to Pneumovax 23, then Prevenar 13, the 13-valent conjugated 
vaccine, can be considered. Where possible, it is important to ensure that patients are responding to 
vaccinations by checking pre- and post-vaccination antibody levels. This is routinely possible for Pneumococcus, 
and serology is also available for other organisms such as Haemophilus influenzae, Meningococcus, diphtheria 
and tetanus toxoids and mumps, measles and rubella viruses. 
The duration of protective antibody status may be shorter in patients on immunosuppressive therapy. Hence, 
the standard advice of a 5-year interval for pneumococcal vaccination may not hold true. Measurement of 
antibody levels, namely serotype-specific pneumococcal antibodies, may help guide vaccination frequency. 
Elkayam et al. showed that most patients did respond to the pneumococcal vaccine, but five (20.8%) of 24 
patients with SLE responded to either none or only one of the seven serotypes tested [56]. 
 
Tuberculosis 
Bacillus Calmette–Guérin (BCG) is not recommended because most cases are related to reactivation, not de 
novo infection; BCG is not always protective against tuberculosis in adults; there is a risk of BCGosis in patients 
on immunosuppressive therapy. In Western countries, there is not a need for anti-tuberculosis prophylaxis. 
However, in areas where tuberculosis is common, for example, India, or in patients of certain ethnic origins, 
there may be a case for anti-tuberculosis prophylaxis [57]. 
 
Influenza 
One should consider vaccination with seasonal influenza annually and with the H1N1 influenza A strain. Studies 
suggest that patients do mount an immune response but perhaps less than healthy controls. Wiesik-Szewczyk et 
al. (2010) showed a lower seroprotection rate after inactivated influenza vaccine in SLE patients compared with 
healthy controls [58]. There were one severe and six mild-to-moderate flares observed in 62 SLE patients. 
Mathian et al. showed that impaired efficacy of H1N1 influenza A vaccine was associated with 
immunosuppressive medication or lymphopaenia [59]. 
Another possible good reason for antimalarials is the following: Borba et al. showed reduced response to 
influenza A/H1N1 in patients taking >20 mg day−1 prednisolone, or on immunosuppressive medication or 
receiving both [60]. The group of patients taking chloroquine had a non-significant difference in seroconversion 
compared to the SLE no-therapy group. However, these findings would need to be corroborated in larger 
studies. 
Azathioprine impaired the response after influenza vaccination in SLE but most patients managed to develop 
protective antibody levels [54] and [55]. 
 
Human papilloma virus 
Cervical smear abnormalities are common in SLE, which may progress to cervical cancer. It may therefore be 
worth considering the use of the quadrivalent HPV vaccination, Gardasil [61]. Mok et al. reported the Gardasil 
vaccine to be safe and reasonably effective in a group of 50 SLE patients [62]. 
 
Thrombo-embolic events after Gardasil vaccination have been reported. Of the 31 reported cases, 90% had a 
risk factor, in fact antiphospholipid syndrome in two cases [63]. It is important to be aware of antiphospholipid 
antibody status in SLE patients so that appropriate measures can be taken. 
 
Herpes zoster 
There are separate varicella zoster (VZV; e.g., Varivax) and herpes zoster (e.g., Zostavax) vaccines. Licenced 
herpes zoster vaccine is a lyophilised preparation of a live, attenuated strain of VZV, which is the same strain 
used in the varicella vaccines. However, its minimum potency is at least 14-times higher than the potency of a 
single-antigen varicella vaccine. Although live vaccines are to be avoided in general for patients receiving 
immunosuppressive therapy, the Advisory Committee on Immunization Practices (ACIP) has made 
recommendations for the herpes zoster vaccine. [64] The committee has proposed that the dose of 
immunosuppressive makes a difference, for example, patients could receive the herpes zoster vaccine if taking 
<0.4 mg kg–1 week–1 methotrexate, <3.0 mg kg−1 azathioprine and a moderate dose of corticosteroids <20 mg 
day−1. Varicella vaccine has been administered without subsequent infection in HIV-infected children with a 
CD4 percentage ≥15% or a CD4 count ≥200 mm–3[65]. Varicella vaccine has also been administered to HIV-
infected subjects with CD4 ≥400 cells μl−1, but was only modestly immunogenic [66]. There are unpublished 
studies for the herpes zoster vaccine in adult HIV patients with a CD4 count ≥200 mm–3 
(http://www.clinicaltrials.gov/ct2/show/NCT00851786?term=zostavax+hiv&rank=1) and in older patients on 
treatment with prednisone 5–20 mg day−1 
(http://www.clinicaltrials.gov/ct2/show/NCT00546819?term=zostavax+corticosteroid&rank=1). Specialist 
advice should be sought from a consultant virologist, when considering live vaccinations in patients receiving 
immunosuppression. 
 
Measles, mumps and rubella 
Measles, mumps and rubella (MMR) is a live vaccine, and most individuals in the UK would have received the 
MMR vaccine as part of their standard childhood immunisation schedule. It is possible to check antibody levels 
to mumps, measles and rubella. Theoretically, as a live vaccine, MMR is contraindicated in patients on 
immunosuppressive therapy. However, the MMR vaccine has been administered without subsequent infection 
to paediatric patients 2 years after bone marrow transplantation [67]. 
EULAR points out that MMR, varicella and herpes zoster vaccine might be exceptions to this rule and may be 
considered in mildly immunosuppressed patients with autoimmune rheumatic disease on a case-by-case basis. 
The authors believe that this is a grey area, and that individual decisions should be made between the 
rheumatologist, clinical immunologist and virologist. 
 
Antibiotic prophylaxis 
No great deal of evidence exists as a basis for antibiotic prophylaxis, though in certain cases use of such an 
approach makes common sense. For example, in patients who develop recurrent infections with a particular 
organism, it may be worth considering prophylactic antimicrobials, at least while they remain on 
immunosuppressant medication. For example, a patient with recurrent herpes zoster infection could be 
considered for prophylaxis with valaciclovir. The herpes zoster vaccine (Zostavax) is live and hence cannot be 
considered in patients receiving a certain level of immunosuppression. A patient developing CMV retinitis on 
azathioprine could be considered for the following: 
▪ checking thiopurine methyltransferase levels, 
▪ an alternative immunosuppressant and 
▪ prophylaxis with valganciclovir. 
Gilliland and Tsokos (2002) suggested antimicrobial prophylaxis in cohorts of patients with increased prevalence 
of certain infections, those who receive heavy doses of immunosuppressive agents or those undergoing 
procedures associated with temporary bacteraemia [68]. 
 
Endocarditis 
Zysset et al. (1987) recommended that patients with SLE who have valvular abnormalities should receive 
endocarditis prophylaxis before invasive dental or genitourinary procedures [69]. 
 
Tuberculosis 
Prophylactic treatment against tuberculosis should be considered in certain ethnic groups of patients with SLE, 
and in certain parts of the world where tuberculosis is common [57]. It is not required in low-risk patients in the 
Western world. 
 
CMV 
CMV infection is an uncommon but potentially fatal opportunistic infection in SLE. Yoon et al. suggested more 
active CMV vigilance and consideration of polymerase chain reaction (PCR)-based CMV prophylaxis in CMV PCR-
positive patients with SLE undergoing intensive immunosuppressive therapy [70]. 
 
PJP 
Gupta et al. reviewed the occurrence of PJP in SLE. They found a low frequency of PJP in SLE patients on 
cyclophosphamide of 0.1588% [71]. They did not recommend routine use of trimethoprim–sulphamethoxazole 
for PJP prophylaxis in SLE patients on cyclophosphamide, except in those with elevated risk, that is, with severe 
leucopenia, lymphopaenia, high-dose corticosteroids, hypocomplementaemia, active renal disease and higher 
mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score [71] and [72]. 
 
Splenectomy and complement 
Patients may have had splenectomy as part of SLE management, such as for thrombocytopaenia. In these cases, 
vaccination with encapsulated bacteria is essential. This should include S. pneumoniae, H. influenzae type b and 
Neisseria meningitidis (A, C, W135 and Y). They should also receive antibiotic prophylaxis with penicillin V. 
In addition, there is evidence of splenic dysfunction in SLE [73], with defective clearance of immune complexes, 
which could include microbial antigens. Low complement levels and acquired reduction of complement receptor 
type 1 on red cell membranes reduce immune complex delivery to the spleen [74]. 
Hepburn and Davies (2002) stress the important relationship between hypocomplementaemia, splenic 
dysfunction and infection in SLE [74]. Infection with S. pneumoniae and N. meningitidis appears to be especially 
important. They have recommended antibiotic prophylaxis in SLE patients with chronic acquired 
hypocomplementaemia, as well as in the very rare genetic complement deficiencies with SLE. With respect to 
the latter, 13 out of 41 patients with C1q deficiency had recurrent bacterial infections, including meningitis and 
pneumonia [75]. 
 
Intravenous immunoglobulin 
Replacement therapy with IVIg is appropriate for primary immune deficiency and can also be very helpful in 
patients with secondary immune deficiency. There are a number of different humoral defects which have been 
described in SLE patients. For example, common variable immune deficiency (CVID), drug-induced 
hypogammaglobulinaemia, hypogammaglobulinaemia related to nephrotic syndrome and specific antibody 
deficiency are all reported [76]. In some cases, the patient may be well though the immunoglobulin levels may 
be low. In these cases, a wait-and-see policy may be appropriate. For example, immunoglobulin levels in 
patients with drug-induced or nephrotic syndrome-related hypogammaglobulinaemia may improve over time. 
Treatment of the nephrotic syndrome should improve the hypogammaglobulinaemia. Drugs implicated in 
causation of hypogammaglobulinaemia include cyclophosphamide and rituximab. The latter does not tend to 
cause hypogammaglobulinaemia after the initial course but only after repeated cycles. Venhoff et al. 
recommended surveying patients post cyclophosphamide and rituximab treatment for serum immunoglobulin 
levels and persisting hypogammaglobulinaemia [77]. In some patients, hypogammaglobulinaemia may be 
associated with an increased risk of infection, particularly of the respiratory tract. Some patients may have 
specific antibody deficiency: that is, normal immunoglobulins but an inability to mount an antibody response to 
specific bacteria, even after vaccinations. 
Therefore, criteria for replacement IVIg therapy in SLE patients should be the presence of 
hypogammaglobulinaemia or specific antibody deficiency, together with a history of recurrent infection. In 
specific antibody deficiency, an additional condition should be that they have not responded to treatment with 
antibiotic prophylaxis. 
The approach to IVIg in these situations would be to administer a replacement dose, rather than the high-dose 
immunomodulatory approach used for suppressing autoimmunity. Immunoglobulin infusions can be 
administered every 3-4 weeks at a dose of approximately 0.4 g kg weight−1 month−1. Treatment for these 
patients should be supervised by a consultant clinical immunologist. 
Monitoring for IVIg consists of measurement of the trough immunoglobulin G (IgG) level, obtained immediately 
prior to an infusion. The target trough level should be 5–10 g l−1, but towards 10 g l−1 if there is established 
respiratory disease such as bronchiectasis. Additional monitoring has traditionally been full blood count (FBC), 
liver function tests (LFTs), hepatitis B surface antigen and hepatitis-C PCR. However, there have been no cases of 
IVIg-acquired viral hepatitis since the mid-1990s, and hence the hepatitis monitoring may become superfluous. 
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Table 1. 
Risk factors for infection. 
Leukopenia 
Acquired hypocomplementaemia 
Genetic complement deficiency 
MBL deficiency 
Hypogammaglobulinaemia 
Splenectomy 
Functional hyposplenism 
Prednisolone dose 
Immunosuppressive medication 
Biologics e.g., rituximab 
MBL = mannose binding lectin. 
 
